CN
753-89-9
应用筛选条件
关键词:'753-89-9'
显示 1-18 共 18 条结果 关于 "753-89-9" 范围 技术文档
XP725 Antibody Number-Lot Number 071M4826
32 53 54 55 56 77 78 79 80
1.3 9 10 11 12 33 34 35 36 57 58 59 60 81 82 83 84
1.4 13 14 15 16 37 38 39 40 61 62 63 64 85 86 87
GR 144053- Non-peptide antagonist of the platelet glycoprotein IIb/IIIa (GP IIb/IIIa) fibrinogen receptor
Ma, Z.Q., et al., Oncogene, 18, 4564-4576 (1999).
114. Cangi, M.G., et al., J. Clin. Invest., 106, 753-761 (2000).
115. Kar, S., et al., Carcinogenesis, 24, 411-416 (2003).
116 Tamura, K., et al., Oncogene
Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease
133, 3058-3061 (1993).
9. Vita, N., et al., FEBS Lett., 335, 1-5 (1993).
10. Vale, W.W., et al., Endocrinologist, 7, 3S-9S (1997).
11. Dautzenberg, F.M., et al., Peptides, 22, 753-760 (2001).
12. Dautzenberg
Protein Tyrosine Phosphatases- Potential Roles in Disease
Ma, Z.Q., et al., Oncogene, 18, 4564-4576 (1999).
114. Cangi, M.G., et al., J. Clin. Invest., 106, 753-761 (2000).
115. Kar, S., et al., Carcinogenesis, 24, 411-416 (2003).
116 Tamura, K., et al., Oncogene
JULABO Catalog 2011 en
- 0.45 11 - 16 9 x 9 / 2x / 37 18 Integrated III (FL) 230/50-60/9 36 x 24 x 54 17 9 162 518 ME-18V
0.23 - 0.45 11 - 16 35 x 41 / 27 45
Validation of Milliflex Quantum for bioburden testing of pharmaceutical products - PDA Journal of Pharmaceutical Science and Technology 2017 71 206-224 (Oliver Gordon et al)
11
98
�
8
27
�
3
25
�
4
9
�
3
8
�
2
5
�
2
5
�
2
A
cc
ur
ac
y
P
-v
al
ue
0.
12
0.
14
0.
21
0.
84
Validation of Milliflex®Quantum for Bioburden Testing of Pharmaceutical Products
11
98
�
8
27
�
3
25
�
4
9
�
3
8
�
2
5
�
2
5
�
2
A
cc
ur
ac
y
P
-v
al
ue
0.
12
0.
14
0.
21
0.
84
XP725 Antibody List Lot 129K4831
7345 UCHL1 P NP_004172.2 , y y y
759 Vinculin V4505 7414 VCL M NP_003364.1 ,NP_054706.1 y y n/d
753 VDAC/Porin V2139 7416 VDAC1 P NP_003365.1 , y y y
259 Ezrin E8897 7430 EZR M NP_001104547.1 y y n/
XP725 Antibody List Lot 129K4830
7345 UCHL1 P NP_004172.2 , y y y
759 Vinculin V4505 7414 VCL M NP_003364.1 ,NP_054706.1 y y n/d
753 VDAC/Porin V2139 7416 VDAC1 P NP_003365.1 , y y y
259 Ezrin E8897 7430 EZR M NP_001104547.1 y y n/
XP725 Antibody List Lot 089K4791
7345 UCHL1 P NP_004172.2 , y y y
759 Vinculin V4505 7414 VCL M NP_003364.1 ,NP_054706.1 y y n/d
753 VDAC/Porin V2139 7416 VDAC1 P NP_003365.1 , y y y
259 Ezrin E8897 7430 EZR M NP_001104547.1 y y n/
Halal Certificate
Isoamyl Propionate Natural W208213 C32918 HC-23SIZR07
752. ISOBORNEOL W215805 C39735 HC-23SILA14
753. ISOBORNYL ACETATE W216003 C37173 HC-23SIWG24
754. ISOBUTYL ACETATE 98%, FCC, FG W217506 B66735
Halal Certificate
Isoamyl Propionate Natural W208213 C32918 HC-22SI6Z28
752. ISOBORNEOL W215805 C39735 HC-22SI4235
753. ISOBORNYL ACETATE W216003 C37173 HC-22SIXD45
754. ISOBUTYL ACETATE 98%, FCC, FG W217506 B66735
XP725 Antibody List
http://www.sigmaaldrich.com/ProductLookup.html?ProdNo=G7670&Brand=SIGMA�
3 9
3 9
3 9
3 9
3 9
3 9
3 9
T 3
3 9
3 9
334 HDAC-7 H6663 56233, 51564 HDAC7A,Hdac7a NP_062518.2,NP_057680.3 M y y n/d
List of Antibodies
C Hydrolase U5258 P y y y
751 Pinin P0084 M y n/d n/d
752 Vanilloid Receptor-1 V2764 P n/d n/d y
753 VDAC/Porin V2139 P y y y
754 Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) V4762 M y n/d
3D BIOPRINTING: Printing a Brighter Future
Mater. 2018, 30, 1802649.
(31) Daly, A. C.; Davidson, M. D.; Burdick, J. A. Nat. Commun. 2021, 12, 753.
(32) Valot, L.; Martinez, J.; Mehdi, A.; Subra, G. Chem. Soc. Rev. 2019, 48,
4049–4086.
(33) Malda
3D BIOPRINTING: Printing a Brighter Future
Mater. 2018, 30, 1802649.
(31) Daly, A. C.; Davidson, M. D.; Burdick, J. A. Nat. Commun. 2021, 12, 753.
(32) Valot, L.; Martinez, J.; Mehdi, A.; Subra, G. Chem. Soc. Rev. 2019, 48,
4049–4086.
(33) Malda
XP725 Antibody List 013M4793
032917.2,NP_001102493.1 M y n/d n/d
752 Vanilloid Receptor-1 V2764 7442 TRPV1 NP_542437.2 P n/d n/d y
753 VDAC/Porin V2139 83529, 7416, 22333 VDAC1,Vdac1 NP_112643.1,NP_003365.1,NP_035824.1 P y y y
754
XP725 Worksheet for Lot Number 071M4826
4 5 hSNF5 INI1 H9912
750 4 4 4 6 hSNF5 INI1 H9912
751 4 4 4 7 iASPP A4605
752 4 4 4 8 iASPP A4605
753 4 4 5 1 IFI16 I1659
754 4 4 5 2 IFI16 I1659
755 4 4 5 3